A coronavirus vaccine is being developed by Ufovax (a spin-off company from Scripps Research), against the novel coronavirus SARS-CoV-2, using its one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology. The vaccine prototype features SARS-CoV-2 protein spikes protruding from a protein nanoparticle scaffold. The nanoparticle vaccine would induce the immune system to rapidly generate antibodies to neutralise or deactivate the coronavirus, offering a recipient protection against the virus. The nanoparticle vaccine consists of self-assembling virus-like particles made from identical proteins. These proteins are synthesised through the insertion of a single plasmid encoding the relevant gene into a CHO or C1 (DYAI) host cell, followed by one-step expression and two subsequent purifications. Early research is underway in the US.
UFOTON platform technology involves creating virus-like particles (VLPs) that present highly stable uncleaved prefusion-optimised proteins, which mimic the native-like, closed state of a viral envelope spike before cell entry occurs, to elicit robust neutralising antibody responses in the host.
Before March 2020, Ufovax acquired exclusive rights to develop and commercialise Scripps Research nanoparticle vaccine technology for certain vaccine targets. 
As of March 2020, Ufovax has patent protection for its one component self-assembling protein nanoparticle (1c-SApNP) vaccine platform technology in the US  .